Venus launches infused combination GI product in India
This article was originally published in Scrip
Venus Remedies of India has launched on the domestic market a combination of the fluoroquinolone antibiotic ofloxacin and the nitroimidazole antiprotozoal compound ornidazole in infusion form, as Mebatic, for severe gastrointestinal infections. The company claims that Mebatic has shown 20-25% improved efficacy over existing therapies. The drug has also been developed with a 'chemical vector' that promotes faster recovery and ensures deeper penetration of the product at the site of infection, it said. GI drugs account for an estimated 11% of the Indian pharmaceutical market.
You may also be interested in...
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, discusses in a wide-ranging interview the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.